Original Article
Long-Term Treatment of Girls with Ornithine Transcarbamylase Deficiency
N Engl J Med 1996; 335:855-860September 19, 1996
- Abstract
Background
Ornithine transcarbamylase is an X-linked mitochondrial enzyme that catalyzes the synthesis of citrulline from carbamoyl phosphate and ornithine. A deficiency of this enzyme leads to hyperammonemia and hyperglutaminemia. In boys the disease is often fatal when its onset occurs during the neonatal period, but it is milder when onset occurs later in childhood. Heterozygous girls may be normal or may have episodes of hyperammonemic encephalopathy and decline in cognitive function. We report here on the long-term outcome in girls with ornithine transcarbamylase deficiency enrolled in studies of treatments designed to activate new pathways of waste-nitrogen excretion.
Methods
We studied 32 girls (age, 1 to 17 years) with ornithine transcarbamylase deficiency who had had at least one episode of encephalopathy. The patients were assigned to treatment that consisted of sodium benzoate, alone or in combination with sodium phenylacetate or sodium phenylbutyrate, or sodium phenylbutyrate alone. Collaborating physicians provided clinical, metabolic, and developmental data at specified intervals.
Results
Patients treated according to these protocols had greater than 90 percent survival at five years and maintained appropriate weight for height. The frequency of hyperammonemic episodes decreased with increasing age and with sodium phenylacetate or sodium phenylbutyrate treatment. Although the mean IQ before treatment was in the low average range, 19 of the 23 girls in whom intelligence was tested longitudinally had stable test scores.
Conclusions
Girls with symptomatic ornithine transcarbamylase deficiency who are treated with drugs that activate new pathways of waste-nitrogen excretion have fewer hyperammonemic episodes and a reduced risk of further cognitive decline.
Media in This Article
Figure 1
Biochemistry of Ornithine Transcarbamylase Deficiency and Its Treatment.Figure 2
Change in IQ Score for 23 Girls with Ornithine Transcarbamylase Deficiency Who Had at Least Two Intelligence Tests after Enrollment in the Treatment Protocols.Article Activity
- Article
Ornithine transcarbamylase (ornithine carbamoyltransferase) deficiency is an X-linked disorder in which the synthesis of citrulline, and hence urea, from carbamoyl phosphate and ornithine is impaired. The consequences include hyperammonemia, hyperglutaminemia, hypoargininemia, hypocitrullinemia, and episodic encephalopathy that, if uncontrolled, results in brain injury and death. The most dramatic form of the disease occurs in newborn boys as catastrophic hyperammonemic encephalopathy; hemizygous males who survive the neonatal period have a poor neurologic outcome, with a high incidence of mental retardation, cerebral palsy, and seizures.1 It is now apparent, however, that the disease may occur in males from the neonatal period through adulthood,2 with late-onset disease associated with a milder phenotype.3 This variable phenotypic expression in males is presumably a result of different mutant alleles, some of which permit residual ornithine transcarbamylase activity.
Clinical manifestations in females carrying a mutation at the ornithine transcarbamylase locus range from apparent normality to profound neurologic impairment.4 Thirteen symptomatic girls ranging in age from 6 months to 14 years at the time of diagnosis all had a history of irritability, vomiting, and lethargy, and most avoided dietary protein.5 Ataxia, progressive encephalopathy, developmental delay, and delayed physical growth each occurred in at least five of the girls, and three had seizures. Five of the 13 girls had IQs of less than 70 at the time of diagnosis, and IQ testing several months later indicated that another 4 had borderline mental retardation (IQ, 70 to 84). Variable expression in females is most likely a function of the proportion of hepatocytes in which the active X chromosome bears the mutant allele, although different mutant alleles may also have varying effects.
Therapy for this disease is directed at decreasing the requirement for urea biosynthesis by decreasing dietary nitrogen intake and by increasing waste-nitrogen excretion (Figure 1Figure 1
Biochemistry of Ornithine Transcarbamylase Deficiency and Its Treatment.). The latter may best be done by prescribing sodium phenylbutyrate, a precursor of sodium phenylacetate that conjugates with glutamine to yield phenylacetylglutamine, a waste-nitrogen compound that is rapidly excreted in the urine.6 For patients treated with phenylbutyrate who have residual ornithine transcarbamylase activity, nitrogen is diverted from the urea cycle and endogenous urea synthesis is suppressed. However, the urea cycle remains functional and may be reactivated to maintain nitrogen homeostasis.6 We report here on the long-term outcome in 32 girls with symptomatic ornithine transcarbamylase deficiency who were enrolled in therapeutic trials of sodium phenylacetate and related compounds before 1991.Methods
Enrollment
From 1979 through 1990, 59 girls less than 18 years of age were referred to the Johns Hopkins Hospital for the evaluation of symptomatic ornithine transcarbamylase deficiency. The diagnosis of ornithine transcarbamylase deficiency was based on orotic aciduria during hyperammonemia and a normal plasma amino acid profile except for increased glutamine and alanine concentrations and decreased citrulline and arginine concentrations. All the patients had had at least one episode of encephalopathy; hepatic ornithine transcarbamylase activity, as measured in 16 patients, ranged from undetectable to 20 percent of normal.
A total of 39 girls were enrolled in a series of protocols approved by the Food and Drug Administration (FDA) and the institutional review boards of the hospitals where they received treatment; informed consent was obtained from all the patients or their parents. Thirty-three girls were white, one was black, three were Hispanic, and two were of mixed racial or ethnic background. They ranged in age from 1 to 17 years (median, 5). In 10 patients the disease was diagnosed at the onset of symptoms; in the other 29 it was diagnosed from 2 months to 12 years (median, 16 months) after the onset of symptoms.
Physicians at 28 institutions in North America and South America collaborated with the authors. Those physicians periodically provided clinical, metabolic, and developmental data, in addition to an assessment of the patients' compliance with therapy. Of the 39 patients, 7 withdrew before five years of follow-up; data on the remaining 32 are presented here.
Therapeutic Protocols
There were three successive drug-treatment protocols,7 each representing an improvement in the efficacy of waste-nitrogen excretion. Patients and physicians were offered the opportunity to adopt the modified protocols as they became available. Protocol 1 (1980 to 1984) included 11 patients (35 patient-years) who received sodium benzoate (0.25 g per kilogram of body weight per day). Protocol 2 (1984 to 1987) included 22 patients (81 patient-years) who received both sodium benzoate (0.25 g per kilo-gram per day) and sodium phenylacetate or sodium phenylbutyrate (0.25 to 0.30 g per kilogram per day). Protocol 3 (1987 to 1996) included 28 patients (165 patient-years) who received sodium phenylbutyrate (0.45 to 0.60 g per kilogram per day or 9.9 to 13.0 g per square meter of body-surface area per day). Each protocol included treatment of hyperammonemic encephalopathy with intravenous sodium benzoate and sodium phenylacetate as needed8 and a reduction of dietary protein intake to the minimum recommended for the patient's age. The diets were supplemented with arginine (free base) or citrulline (174 mg per kilogram per day or 3.8 g per square meter per day); essential amino acid supplementation was not recommended.
To monitor growth and assess nutritional status, the software program Anthro, version 1.01,9 was used to calculate age-specific z scores (the number of standard deviations above or below the mean) for each measurement. Descriptive statistics were calculated with SPSS for Windows, version 6.1.
Cognitive Measurements
Standardized intelligence tests were administered to 23 girls at least twice after treatment was begun. Of the nine girls who did not undergo sequential testing, four were profoundly retarded at the time of enrollment. The tests were the Cattell Infant Intelligence Test, McCarthy Scales of Children's Abilities, Slosson Intelligence Test, Stanford–Binet Intelligence Scale (forms LM and IV), Wechsler Preschool and Primary Scale of Intelligence (WPPSI), Wechsler Intelligence Scale for Children — Revised (WISC-R), Wechsler Intelligence Scale for Children — III (WISC-III), and Wechsler Adult Intelligence Scale — Revised (WAIS-R). The results of the first test administered after the patient began treatment were used as the base-line measure of intelligence, and the most recent test results were used to assess changes in IQ. The length of time between the tests ranged from 1.1 to 11.2 years.
Results
Survival
There were 3 deaths among the 32 patients. One patient, who was profoundly retarded and had severe cerebral palsy, died of aspiration pneumonia in the absence of hyperammonemia after 11 months of therapy. One patient died during a hyperammonemic episode at 16 years of age, four years after diagnosis; her intellectual level was average when tested after two years of treatment. Anecdotal information suggests that the ingestion of an abortifacient may have contributed to her terminal hyperammonemic episode. In the third patient the disease was diagnosed at 14 months of age; despite excellent compliance with treatment, she had numerous hyperammonemic episodes and died at 8 years of age during hospitalization for hyperammonemia unresponsive to treatment.
Anthropometric Measurements
The mean (±SD) birth weight of the patients was 3.8±0.8 kg. At the time of enrollment, the mean weight-for-age and height-for-age z scores were slightly below the mean derived from National Center for Health Statistics and Centers for Disease Control and Prevention reference data10; these findings were consistent with the history of poor weight gain, weight loss, and delayed growth noted at the time of diagnosis.
We calculated mean z scores for five-year age intervals (Table 1Table 1
Anthropometric Measurements in Girls with Ornithine Transcarbamylase Deficiency, According to Age.) and five-year treatment intervals (data not shown), because the age at entry varied among the patients. Both height-for-age and weight-for-age z scores for the patients in this study were below the mean (i.e., below zero) but remained relatively constant with increasing age. The z scores for weight for height were above the mean, indicating that although these patients tended to be small, their weight was appropriate for their height.Hyperammonemic Episodes
After enrollment, 23 patients had episodes of hyperammonemia requiring hospitalization for intravenous sodium benzoate and sodium phenylacetate therapy (Table 2Table 2
Hyperammonemic Episodes during Treatment of Girls with Ornithine Transcarbamylase Deficiency, According to Therapeutic Protocol.).8 The patients receiving phenylacetate or phenylbutyrate (protocol 2 or 3) had fewer episodes than those receiving sodium benzoate alone (protocol 1). This observation is consistent with evidence from patients with other urea-cycle defects11 and confirms that phenylacetylglutamine is superior to hippurate as a waste-nitrogen vehicle.6 Treated girls under five years of age had an average of one episode of hyperammonemia per year (Table 3Table 3
Hyperammonemic Episodes during Treatment of Girls with Ornithine Transcarbamylase Deficiency, According to Age.). This frequency declined with increasing age, suggesting that the risk decreases during puberty. During the 29 patient-years of treatment for patients 20 years of age or older, only three hyperammonemic episodes occurred. This trend was similar for all three protocols, suggesting that the risk of hyperammonemia decreases with increasing age, independently of therapy.There was wide variation among patients in the frequency of episodes. Nine patients had no hyperammonemic episodes after enrollment; their mean length of treatment was seven years. Twenty patients had 1 episode or less per year (mean, 0.4 episode; range, 0.1 to 1.0); their mean length of treatment was eight years. The remaining three surviving patients each had 10 or more hyperammonemic episodes; their average length of treatment was 11 years, and the frequency of episodes ranged from 1 to 3 per year.
Cognitive Development
At the time of initial testing, the IQ scores of the 23 girls in whom intelligence was tested longitudinally ranged from 56 to 111 (mean, 84), with 10 girls having scores below 80. At follow-up, their scores ranged from 36 to 116. The correlation between the IQ scores at initial testing and follow-up was 0.9 (P<0.001). Of the 23 girls, only 4 had changes in IQ that exceeded 15 points (the equivalent of 1 SD); these were all decreases. The change in IQ was not affected by the length of the interval between tests, the age at first testing, the initial IQ, or the number of years of treatment. The change in IQ in relation to the interval between tests is shown in Figure 2Figure 2
Change in IQ Score for 23 Girls with Ornithine Transcarbamylase Deficiency Who Had at Least Two Intelligence Tests after Enrollment in the Treatment Protocols..Scores on the verbal and performance subtests were compared in the 13 girls who had these tests more than once. At initial testing, 6 of the 13 had significantly higher verbal than performance scores. The differences ranged from 14 to 23 points; a difference of 15 points was statistically significant (P = 0.01). All six girls had a narrowing of the verbal–performance difference on their second test, as did two other girls whose verbal–performance difference was small at initial testing. Greater verbal–performance differences were not related to the age at first testing or to the overall IQ score.
Discussion
We report here on the long-term outcome of symptomatic girls with ornithine transcarbamylase deficiency who were treated with drugs that provide an alternative vehicle for waste-nitrogen excretion. Each had had at least one episode of potentially life-threatening encephalopathy before enrollment, and all presumably remained vulnerable to episodic hyperammonemia. The goal of treatment was to improve survival and maintain cognitive functioning by reducing the risk of hyperammonemic episodes.
The authors, funding agencies, and the Johns Hopkins Joint Committee on Clinical Investigations all agreed that ethical issues precluded a controlled clinical trial to compare the outcomes in treated and untreated girls. Thus, there are no studies of untreated girls with symptomatic ornithine transcarbamylase deficiency with which these results can be compared. However, historical data suggest a high rate of mortality from coma among untreated carrier females12; among a selected group from 17 pedigrees, 9 deaths occurred during 11 episodes of coma (82 percent mortality). In our study over 90 percent of the girls treated according to these protocols survived for at least five years, suggesting that the treatment reduced the frequency of hyperammonemic encephalopathy and the consequent risk of death.
Treatment with sodium phenylacetate or sodium phenylbutyrate, which activates the synthesis of phenylacetylglutamine containing two waste-nitrogen atoms (Figure 1), decreased the frequency of hyperammonemic episodes by approximately 40 percent, as compared with treatment with sodium benzoate, which activates the synthesis of a product containing only one waste-nitrogen atom. This suggests that treatment that improves waste-nitrogen excretion stabilizes plasma ammonium concentrations and reduces the frequency of hyperammonemic episodes in these patients. Although it would have been desirable to compare the frequency of episodes before and after treatment began, such a comparison was hampered both by the wide phenotypic variation among these patients and by the difficulties of retrospectively interpreting physicians' and parents' descriptions of lethargy, irritability, and sleepiness.
Historical data suggest that subtle cerebral damage may occur in untreated carriers, despite the absence of overt symptoms.4 Our findings that four patients were profoundly retarded at or shortly after diagnosis and that the initial mean IQ score among those tested repeatedly was only 84 (low average) support the hypothesis that many, if not all, untreated symptomatic girls are on a trajectory of cognitive decline. Our analysis of intelligence-test performance clearly indicates that intellectual functioning has remained stable for more than 80 percent of the 23 girls enrolled in these treatment protocols in whom intelligence was tested longitudinally. Further, the change in IQ in three of the four girls who had a substantial decline may be a testing artifact, resulting in part from use of two different forms of the Stanford–Binet test (LM and IV)13 and Wechsler Intelligence Scale for Children (WISC-R and WISC-III).14
Although these results suggest that treatment that reduces the risk of hyperammonemic episodes is effective in improving survival and stabilizing cognitive functioning, the treatment outcome for any individual girl cannot be predicted and is most likely due to a combination of unmeasurable factors, including residual ornithine transcarbamylase activity, the degree of adherence to a low-protein diet, the degree of compliance with the therapeutic regimen, environmental stresses, and genetic factors. It is also important to note that our results are limited to girls whose symptoms brought them to the attention of a referral center; whether ostensibly normal heterozygous girls might benefit from treatment is not known.
Supported by grants from the National Institutes of Health (HD11134, HD26358, and HD29004) and the Food and Drug Administration (FDR000198).
Dr. Brusilow has an indirect equity interest in and is an employee of Ucyclyd Pharma, which will be marketing sodium phenylbutyrate. He also receives royalties from the sales of sodium benzoate–sodium phenylacetate (Ucephan, McGaw).
We are indebted to Mrs. Ellen Gordes for her excellent technical assistance and to Drs. W. Adkins, P. Arn, G. Arnold, B. Barron, D. Bartholomew, G. Davidson, C.-T. Fong, J. Fox, N. Glick, E. Guevara, C. Harding, J. Heubi, L. Hill, A. Horwich, J. Irvine, D. Kerr, M. Korson, C. Leonard, H. Levy, P. Mamunes, R. Matalon, M. Miller, L. Mosovich, J. Munser, J. Nicholson, A. Rachmel, W. Rhead, L. Rutledge, R. Saborio, J. Sharp, R. Sprunk, R. Stone, J. Thoene, R. Wappner, J. Ward, S. Werlin, C. Wharton, L. Wong, and A. Zinn for participating in this collaborative study.
Source Information
From the Departments of Pediatrics (N.E.M., S.W.B., D.B.C.) and Psychiatry (S.S.B.), Johns Hopkins University School of Medicine, Baltimore.
Address reprint requests to Dr. Maestri at the Department of Pediatrics, Johns Hopkins Hospital, Park 336, 600 N. Wolfe St., Baltimore, MD 21287-2539.
- References
References
1
Msall M ,Batshaw ML ,Suss R ,Brusilow SW ,Mellits ED . Neurologic outcome in children with inborn errors of urea synthesis: outcome of urea-cycle enzymopathies. N Engl J Med 1984;310:1500-1505
Full Text | Web of Science | Medline2
Brusilow SW. Urea cycle disorders: clinical paradigm of hyperammonemic encephalopathy. In: Boyer JL, Ockner RK, eds. Progress in liver disease. Vol. 13. Philadelphia: W.B. Saunders, 1995:293-309.
3
Finkelstein JE ,Hauser ER ,Leonard CO ,Brusilow SW . Late-onset ornithine transcarbamylase deficiency in male patients. J Pediatr 1990;117:897-902[Erratum, J Pediatr 1991;118:326.]
CrossRef | Web of Science | Medline4
Batshaw ML ,Roan Y ,Jung AL ,Rosenberg LA ,Brusilow SW . Cerebral dysfunction in asymptomatic carriers of ornithine transcarbamylase deficiency. N Engl J Med 1980;302:482-485
Full Text | Web of Science | Medline5
Rowe PC ,Newman SL ,Brusilow SW . Natural history of symptomatic partial ornithine transcarbamylase deficiency. N Engl J Med 1986;314:541-547
Full Text | Web of Science | Medline6
Brusilow SW ,Finkelstein JE . Restoration of nitrogen homeostasis in a man with ornithine transcarbamylase deficiency. Metabolism 1993;42:1336-1339
CrossRef | Web of Science | Medline7
Brusilow SW ,Maestri NE . Urea cycle disorders: diagnosis, pathophysiology, and therapy. Adv Pediatr 1996;43:127-170
Medline8
Brusilow SW ,Danney M ,Waber LJ , et al. Treatment of episodic hyperammonemia in children with inborn errors of urea synthesis. N Engl J Med 1984;310:1630-1634
Full Text | Web of Science | Medline9
Sullivan KM, Gorstein J. ANTHRO: software for calculation of pediatric anthropometry, version 1.01. Atlanta: Centers for Disease Control, 1990 (software and manual).
10
Dibley MJ ,Goldsby JB ,Staehling NW ,Trowbridge FL . Development of normalized curves for the international growth reference: historical and technical considerations. Am J Clin Nutr 1987;46:736-748
Web of Science | Medline11
Maestri NE ,Clissold DB ,Brusilow SW . Long-term survival of patients with argininosuccinate synthetase deficiency. J Pediatr 1995;127:929-935
CrossRef | Web of Science | Medline12
Batshaw ML ,Msall M ,Beaudet AL ,Trojak J . Risk of serious illness in heterozygotes for ornithine transcarbamylase deficiency. J Pediatr 1986;108:236-241
CrossRef | Web of Science | Medline13
Sattler JM. Assessment of children revised and updated. 3rd ed. San Diego: JM Sattler, 1992.
14
Wechsler D. Manual for the Wechsler Intelligence Scale for Children. 3rd ed. San Antonio, Tex.: Psychological Corporation, 1991.
- Citing Articles (57)
Citing Articles
1
Pedro Ayala, José Montenegro, Raúl Vivar, Alan Letelier, Pablo Aránguiz Urroz, Miguel Copaja, Deisy Pivet, Claudio Humeres, Rodrigo Troncoso, José Miguel Vicencio, Sergio Lavandero, Guillermo Díaz-Araya. (2012) Attenuation of endoplasmic reticulum stress using the chemical chaperone 4-phenylbutyric acid prevents cardiac fibrosis induced by isoproterenol. Experimental and Molecular Pathology 92:1, 97-104
CrossRef2
Jun Kido, Kimitoshi Nakamura, Hiroshi Mitsubuchi, Toshihiro Ohura, Masaki Takayanagi, Masafumi Matsuo, Makoto Yoshino, Yosuke Shigematsu, Tohru Yorifuji, Mureo Kasahara, Reiko Horikawa, Fumio Endo. (2011) Long-term outcome and intervention of urea cycle disorders in Japan. Journal of Inherited Metabolic Disease
CrossRef3
Seung-Ah Lee, Olga V. Belyaeva, Natalia Y. Kedishvili. (2011) Evidence that proteosome inhibitors and chemical chaperones can rescue the activity of retinol dehydrogenase 12 mutant T49M. Chemico-Biological Interactions 191:1-3, 55-59
CrossRef4
Samar H Ibrahim, Rohit Kohli, Gregory J Gores. (2011) Mechanisms of Lipotoxicity in NAFLD and Clinical Implications. Journal of Pediatric Gastroenterology and Nutrition1
CrossRef5
J.C. Chamcheu, I. Pihl-Lundin, C.E. Mouyobo, T. Gester, M. Virtanen, A. Moustakas, H. Navsaria, A. Vahlquist, H. Törmä. (2011) Immortalized keratinocytes derived from patients with epidermolytic ichthyosis reproduce the disease phenotype: a useful in vitro model for testing new treatments. British Journal of Dermatology 164:2, 263-272
CrossRef6
C. Jörck, W. Kiess, J. F. W. Weigel, U. Mütze, U. Bierbach, S. Beblo. (2011) Transient Hyperammonemia Due to L -Asparaginase Therapy in Children with Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma. Pediatric Hematology-Oncology 28:1, 3-9
CrossRef7
Taketomo Mizukami, Kazumasa Orihashi, Bagus Herlambang, Shinya Takahashi, Makoto Hamaishi, Kenji Okada, Taijiro Sueda. (2010) Sodium 4-phenylbutyrate protects against spinal cord ischemia by inhibition of endoplasmic reticulum stress. Journal of Vascular Surgery 52:6, 1580-1586
CrossRef8
A. L. Gropman, B. Gertz, K. Shattuck, I. L. Kahn, R. Seltzer, L. Krivitsky, J. Van Meter. (2010) Diffusion Tensor Imaging Detects Areas of Abnormal White Matter Microstructure in Patients with Partial Ornithine Transcarbamylase Deficiency. American Journal of Neuroradiology 31:9, 1719-1723
CrossRef9
Jennifer M Anderson, Michael C Brodsky. (2010) Protracted Cortical Visual Loss in a Child With Ornithine Transcarbamylase Deficiency. Journal of Neuro-Ophthalmology 30:1, 99-101
CrossRef10
Kimberly Powell, Kim Van Naarden Braun, Rani Singh, Stuart K. Shapira, Richard S. Olney, Marshalyn Yeargin-Allsopp. (2010) Prevalence of Developmental Disabilities and Receipt of Special Education Services among Children with an Inborn Error of Metabolism. The Journal of Pediatrics 156:3, 420-426
CrossRef11
Janneke M. Stapelbroek, Karel J. van Erpecum, Leo W.J. Klomp, Roderick H.J. Houwen. (2010) Liver disease associated with canalicular transport defects: Current and future therapies. Journal of Hepatology 52:2, 258-271
CrossRef12
Jennifer Seminara, Mendel Tuchman, Lauren Krivitzky, Jeffrey Krischer, Hye-Seung Lee, Cynthia LeMons, Matthias Baumgartner, Stephen Cederbaum, George A. Diaz, Annette Feigenbaum, Renata C. Gallagher, Cary O. Harding, Douglas S. Kerr, Brendan Lanpher, Brendan Lee, Uta Lichter-Konecki, Shawn E. McCandless, J. Lawrence Merritt, Mary Lou Oster-Granite, Margretta R. Seashore, Tamar Stricker, Marshall Summar, Susan Waisbren, Marc Yudkoff, Mark L. Batshaw. (2010) Establishing a consortium for the study of rare diseases: The Urea Cycle Disorders Consortium. Molecular Genetics and Metabolism 100, S97-S105
CrossRef13
Philippe M. Campeau, Penelope J. Pivalizza, Geoffrey Miller, Kim McBride, Saul Karpen, John Goss, Brendan H. Lee. (2010) Early orthotopic liver transplantation in urea cycle defects: Follow up of a developmental outcome study. Molecular Genetics and Metabolism 100, S84-S87
CrossRef14
H. Ito, N. Yoshimura, M. Kurosawa, S. Ishii, N. Nukina, H. Okazawa. (2009) Knock-down of PQBP1 impairs anxiety-related cognition in mouse. Human Molecular Genetics 18:22, 4239-4254
CrossRef15
Kazuhiko Ono, Miyuki Ikemoto, Takeshi Kawarabayashi, Masaki Ikeda, Takuya Nishinakagawa, Masato Hosokawa, Mikio Shoji, Mitsuo Takahashi, Manabu Nakashima. (2009) A chemical chaperone, sodium 4-phenylbutyric acid, attenuates the pathogenic potency in human α-synuclein A30P+A53T transgenic mice. Parkinsonism & Related Disorders 15:9, 649-654
CrossRef16
LAUREN KRIVITZKY, TALIN BABIKIAN, HYE-SEUNG LEE, NINA HATTIANGADI THOMAS, KAREN L. BURK-PAULL, MARK L. BATSHAW. (2009) Intellectual, Adaptive, and Behavioral Functioning in Children With Urea Cycle Disorders. Pediatric Research 66:1, 96-101
CrossRef17
M. Bürle, H. Mende, U. Plum, M. Bluthardt, M. Walka, G. Geldner. (2009) Ornithintranscarbamylasemangel im Jugend- und Erwachsenenalter. Der Anaesthesist 58:6, 594-601
CrossRef18
Patricia Kane, Annette Cartaxo. 2009. Seizures. .
CrossRef19
Lale Ozcan, Ayse Seda Ergin, Allen Lu, Jason Chung, Sumit Sarkar, Duyu Nie, Martin G. Myers, Umut Ozcan. (2009) Endoplasmic Reticulum Stress Plays a Central Role in Development of Leptin Resistance. Cell Metabolism 9:1, 35-51
CrossRef20
Vikrant Mittal, Sunanda Muralee, Rajesh R. Tampi. (2009) Valproic Acid-Induced Hyperammonemia in the Elderly: A Review of the Literature. Case Reports in Medicine 2009, 1-5
CrossRef21
Nitin Jain, Adriana Rossi, Guillermo Garcia-Manero. (2009) Epigenetic therapy of leukemia: An update. The International Journal of Biochemistry & Cell Biology 41:1, 72-80
CrossRef22
John M. Gansner, Jonathan D. Gitlin. (2008) Essential role for the alpha 1 chain of type VIII collagen in Zebrafish notochord formation. Developmental Dynamics 237:12, 3715-3726
CrossRef23
Kavita Kalidas, Réza Behrouz. (2008) Inherited metabolic disorders and cerebral infarction. Expert Review of Neurotherapeutics 8:11, 1731-1741
CrossRef24
A. Hackett, J. Gillard, B. Wilcken. (2008) n of 1 trial for an ornithine transcarbamylase deficiency carrier. Molecular Genetics and Metabolism 94:2, 157-161
CrossRef25
Keli Hansen, Simon Horslen. (2008) Metabolic liver disease in children. Liver Transplantation 14:5, 713-733
CrossRef26
Keli Hansen, Simon Horslen. (2008) Metabolic liver disease in children. Liver Transplantation 14:4, 391-411
CrossRef27
Patrick Hines, George J. Dover, Linda M.S. Resar. (2008) Pulsed-dosing with oral sodium phenylbutyrate increases hemoglobin F in a patient with sickle cell anemia. Pediatric Blood & Cancer 50:2, 357-359
CrossRef28
Masatoshi Inden, Yoshihisa Kitamura, Hiroki Takeuchi, Takashi Yanagida, Kazuyuki Takata, Yuka Kobayashi, Takashi Taniguchi, Kanji Yoshimoto, Masahiko Kaneko, Yasunobu Okuma, Takahiro Taira, Hiroyoshi Ariga, Shun Shimohama. (2007) Neurodegeneration of mouse nigrostriatal dopaminergic system induced by repeated oral administration of rotenone is prevented by 4-phenylbutyrate, a chemical chaperone. Journal of Neurochemistry 101:6, 1491-1504
CrossRef29
Yung-Yue Jeng, Nien-Ting Lin, Pen-Heng Chang, Yuan-Ping Huang, Victor Fei Pang, Chen-Hsuan Liu, Chung-Tien Lin. (2007) Retinal ischemic injury rescued by sodium 4-phenylbutyrate in a rat model. Experimental Eye Research 84:3, 486-492
CrossRef30
Edward A. Burton, David J. Fink, Joseph C. Glorioso. 2006. Vectors and Gene Therapy. .
CrossRef31
Hironori Nagasaka, Tohru Yorifuji, Kei Murayama, Mitsuru Kubota, Keiji Kurokawa, Tomoko Murakami, Masaki Kanazawa, Tomozumi Takatani, Atsushi Ogawa, Emi Ogawa, Shigenori Yamamoto, Masanori Adachi, Kunihiko Kobayashi, Masaki Takayanagi. (2006) Effects of arginine treatment on nutrition, growth and urea cycle function in seven Japanese boys with late-onset ornithine transcarbamylase deficiency. European Journal of Pediatrics 165:9, 618-624
CrossRef32
Juan C. Marini, Suzanne R. Broussard. (2006) Hyperammonemia increases sensitivity to LPS. Molecular Genetics and Metabolism 88:2, 131-137
CrossRef33
(2006) Congenital Glutamine Deficiency with Glutamine Synthetase Mutations. New England Journal of Medicine 354:10, 1093-1094
Full Text34
P Maslak, S Chanel, L H Camacho, S Soignet, P P Pandolfi, I Guernah, R Warrell, S Nimer. (2006) Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome. Leukemia 20:2, 212-217
CrossRef35
Naoki Kawagishi, Kazushige Satoh, Yoshitaka Enomoto, Yorihiro Akamatsu, Satoshi Sekiguchi, Akira Satoh, Keisei Fujimori, Yuhei Takasago, Tetsuya Ito, Toshihiro Ohura, Susumu Satomi. (2005) Improved Quality of Life and Unchanged Magnetic Resonance Brain Imaging After Living Donor Liver Transplantation for Late-Onset Ornithine Transcarbamylase Deficiency: Report of a Case. Surgery Today 35:12, 1087-1091
CrossRef36
Raffaele Iorio, Angela Sepe, Antonietta Giannattasio, Francesco Cirillo, Angela Vegnente. (2005) Hypertransaminasemia in childhood as a marker of genetic liver disorders. Journal of Gastroenterology 40:8, 820-826
CrossRef37
Mariposa McCall, James A. Bourgeois. (2004) Valproic Acid-Induced Hyperammonemia. Journal of Clinical Psychopharmacology 24:5, 521-526
CrossRef38
Joseph J. Bahl, Richard L. De Armond, Rubin Bressler. (2004) Multisite inhibition by phenylacetate of PC-3 cell growth. Anti-Cancer Drugs 15:5, 513-523
CrossRef39
Andrea L Gropman, Mark L Batshaw. (2004) Cognitive outcome in urea cycle disorders. Molecular Genetics and Metabolism 81, 58-62
CrossRef40
David C. Rishikof, Dennis A. Ricupero, Hanqiao Liu, Ronald H. Goldstein. (2004) Phenylbutyrate decreases type I collagen production in human lung fibroblasts. Journal of Cellular Biochemistry 91:4, 740-748
CrossRef41
Kunsang Gyato, J. Wray, Z. J. Huang, M. Yudkoff, Mark L. Batshaw. (2004) Metabolic and neuropsychological phenotype in women heterozygous for ornithine transcarbamylase deficiency. Annals of Neurology 55:1, 80-86
CrossRef42
Linda M.S. Resar, Jodi B. Segal, Lorna K. Fitzpatric, Alison Friedmann, Saul W. Brusilow, George J. Dover. (2002) Induction of Fetal Hemoglobin Synthesis in Children With Sickle Cell Anemia on Low-Dose Oral Sodium Phenylbutyrate Therapy. Journal of Pediatric Hematology/Oncology 24:9, 737-741
CrossRef43
Asad Mian, Brendan Lee. (2002) Urea-cycle disorders as a paradigm for inborn errors of hepatocyte metabolism. Trends in Molecular Medicine 8:12, 583-589
CrossRef44
DAVID H. PERLMUTTER. (2002) Chemical Chaperones: A Pharmacological Strategy for Disorders of Protein Folding and Trafficking. Pediatric Research 52:6, 832-836
CrossRef45
Lei Chen, Ali Vaezy, Margretta R. Seashore, Carl R. Baum. (2002) Emesis, Confusion, and Visual Loss in an Adolescent. Pediatric Case Reviews 2:4, 240-247
CrossRef46
SAUL W. BRUSILOW. (2002) Hyperammonemic Encephalopathy. Medicine 81:3, 240-249
CrossRef47
Shigeru Honda, Koujirou Yamamoto, Masayuki Sekizuka, Yasuo Oshima, Kazumi Nagai, Gen-ichi Hashimoto, Hiroaki Kaneko, Takeshi Tomomasa, Yuko Konno, Ryuya Horiuchi. (2002) Successful Treatment of Severe Hyperammonemia Using Sodium Phenylacetate Powder Prepared in Hospital Pharmacy. Biological & Pharmaceutical Bulletin 25:9, 1244-1246
CrossRef48
Annick Legras, François Labarthe, François Maillot, Marie-Ange Garrigue, Achille Kouatchet, Hélène Ogier de Baulny. (2002) Late diagnosis of ornithine transcarbamylase defect in three related female patients: Polymorphic presentations. Critical Care Medicine 30:1, 241-244
CrossRef49
M.C. McGuinness, H.-P. Zhang, K.D. Smith. (2001) Evaluation of Pharmacological Induction of Fatty Acid β-Oxidation in X-Linked Adrenoleukodystrophy. Molecular Genetics and Metabolism 74:1-2, 256-263
CrossRef50
Alberto B. Burlina, Helen Ogier, Herbert Korall, Friedrich K. Trefz. (2001) Long-Term Treatment with Sodium Phenylbutyrate in Ornithine Transcarbamylase-Deficient Patients. Molecular Genetics and Metabolism 72:4, 351-355
CrossRef51
Paul Linsdell. (2001) Direct block of the cystic fibrosis transmembrane conductance regulator Cl− channel by butyrate and phenylbutyrate. European Journal of Pharmacology 411:3, 255-260
CrossRef52
Martina C McGuinness, Heming Wei, Kirby D Smith. (2000) Therapeutic developments in peroxisome biogenesis disorders. Expert Opinion on Investigational Drugs 9:9, 1985-1992
CrossRef53
William B. Rizzo. (2000) Peroxisome 1, 2, 3 ?. Annals of Neurology 47:3, 281-283
CrossRef54
Heming Wei, Stephan Kemp, Martina C. McGuinness, Ann B. Moser, Kirby D. Smith. (2000) Pharmacological induction of peroxisomes in peroxisome biogenesis disorders. Annals of Neurology 47:3, 286-296
CrossRef55
Stephan Kemp, He-Ming Wei, Jyh-Feng Lu, Lelita T Braiterman, Martina C. McGuinness, Ann B. Moser, Paul A. Watkins, Kirby D. Smith. (1998) Gene redundancy and pharmacological gene therapy: Implications for X-linked adrenoleukodystrophy. Nature Medicine 4:11, 1261-1268
CrossRef56
Nancy E. Maestri, Carolyn Lord, Michael Glynn, Allen Bale, Saul W. Brusilow. (1998) The Phenotype of Ostensibly Healthy Women Who Are Carriers for Ornithine Transcarbamylase Deficiency. Medicine 77:6, 389-397
CrossRef57
Ashley A. Busuttil, John A. Goss, Philip Seu, Tom S. Dulkanchainun, George S. Yanni, Sue V. McDiarmid, Ronald W. Busuttil. (1998) The role of orthotopic liver transplantation in the treatment of ornithine transcarbamylase deficiency. Liver Transplantation and Surgery 4:5, 350-354
CrossRef
